Despite the abundance of new therapies designed to delay or prevent kidney and cardiovascular events in people with type 2 diabetes (T2D), there remains a stark gap in the evidence supporting their efficacy and safety for other types of diabetes. Individuals without T2D are frequently excluded from clinical trials based on the assumptions that their event risk, pathogenesis, and potential for adverse events differ significantly. It is anticipated that treatments will eventually be expanded to include this population, yet the uptake of new therapies even with clear evidence is often disappointingly low.